Skip to content

Effect of nutritional supplementation therapy of sarcopenia in the elderly over 70 years old: A randomized, controlled trial

Effect of nutritional supplementation therapy of sarcopenia in the elderly over 70 years old: A randomized, controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049858
Enrollment
Unknown
Registered
2021-08-10
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Experimental Group:whey protein-based nutritional formula supplementation
Control group:iso-caloric control formula supplementation

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
70 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 70 years old; 2. BMI<30kg/m2 3. Diagnosed with sarcopenia; 4. Willing to participate in this study and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are participating in clinical trials of other drugs; 2. Patients with severe cardiovascular disease (NYHA class III-IV), severe aortic stenosis, previous history of cardiac arrest, installation of pacemaker or internal automatic defibrillator, and repeated angina pectoris in the past six months; 3. Patients with severe cerebrovascular disease (hemiplegia and poor mobility after previous stroke) and Parkinson's disease; 4. Patients with severe cognitive impairment (MMSE 150umol/L, or eGFR<=30ml/min), hepatic insufficiency (Child-Pugh BC grade), calcium metabolism disorders (including but not limited to abnormal parathyroid gland function) , secondary osteoporosis), hyperthyroidism, immunodeficiency diseases, other serious diseases that may threaten life, such as cancer (cancer-related treatment within the past 3 years); 6. Suffering from muscle disease, taking drugs that affect muscle function; suffering from diseases affecting limb movement, such as patients with severe joint disease (including but not limited to osteoarthritis or rheumatoid arthritis, patients undergoing joint replacement surgery), the installation of prosthetic limbs patient; 7. Patients who have undergone surgery within the past 1 month; 8. Actively lose weight or gain weight in the past six months, and take drugs that may cause weight changes (such as hormones, nutritional supplements, protein powder, amino acid health products); 9. Survival time due to a major disease, expected survival time < 6 months; 10. Patients who are allergic to ingredients in nutritional intervention preparations.

Design outcomes

Secondary

MeasureTime frame
Skeletal muscle mass;Grip strength;Short Physical Performance Battery;

Countries

China

Contacts

Public ContactLuo Man

Zhongshan Hospital, Fudan University

luo.man@zs-hospital.sh.cn+86 13918065668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026